Vital Therapies and Immunic Therapeutics Announce Transaction to Create Leading Inflammatory and Autoimmune Disease Company
Probiodrug to Attend and Present at European and US Conferences in February 2016
NOXXON PHARMA HOSTS KEY OPINION LEADER SYMPOSIUM
Key patents granted for Probiodrug's pGlu-Abeta targeting monoclonal antibody program for the treatment of Alzheimer's disease
Parlamentsgebäude in Belfast mit Calyxo Modulen
Noxxon AG will an die Euronext
Börse-Online - Branchenreport
Probiodrug announces pricing of a EUR 13.5 million private placement of new shares
Probiodrug gibt Kapitalerhöung bekannt
Probiodrug AG to Publish its Third Quarter 2015 Business Update on November 19, 2015